-
4 days ago | 
themedicinemaker.com | Stephanie Vine
“Depending on the country, only about two in 10 eligible patients, on average, receive CAR T-cell therapy. These are potentially curative therapies, so a major area for us is realizing the full potential of CAR T and ensuring more patients have access. This means meeting patients where they are.
-
4 days ago | 
themedicinemaker.com | Stephanie Vine
We’ve been publishing content for over a decade – and among my favourite features is our esteemed “Sitting Down With” interview series, which looks at the careers and achievements of outstanding individuals. Over the years, we’ve had the opportunity to speak to some incredible names and learn some amazing stories.
-
5 days ago | 
themedicinemaker.com | Stephanie Vine
The Golden Ticket program targets early-stage biotechs that “want to change the world,” with a focus on cardiometabolic health and rare blood and rare endocrine disorders. The prize includes rent-free space, mentoring and support from both Novo Nordisk and the Pioneer Group, and access to Pioneer’s venture programs. Entry closed in November 2024, with shortlisted companies invited to a pitching event. And the winner?
-
6 days ago | 
themedicinemaker.com | Stephanie Vine
FUJIFILM Diosynth Biotechnologies and Regeneron Pharmaceuticals have signed a 10-year manufacturing agreement valued at more than $3 billion. Under the agreement, FUJIFILM Diosynth will manufacture commercial and clinical biologics for Regeneron at its new facility in Holly Springs, North Carolina.
-
1 week ago | 
themedicinemaker.com | Stephanie Vine
Click here to read Part 1. In the late 90s, I was part of a major project team implementing a new ERP IT infrastructure. It was an exciting time – right before the year 2000. It was a significant investment and became a cornerstone of our future success. At that point, Colorcon was an international business, but hadn’t fully transitioned to a global structure. This IT project changed that, and our value proposition became clear because we had become a highly integrated organization.
-
1 week ago | 
themedicinemaker.com | Stephanie Vine
I was born in the UK, where I studied at university and then started work with Colorcon in 1996. My first role within Colorcon was as a bench chemist, helping to develop new products to support the pharmaceutical industry. I approached my manager at the time about the possibility of transferring to the US – and fortunately, they were looking for technical expertise there so it was a very natural transition.
-
1 week ago | 
themedicinemaker.com | Stephanie Vine
Researchers from the Fred Hutchinson Cancer Center and Seidman Cancer Center have outlined foundational steps and quality considerations for establishing and maintaining GMP cell processing programs in academic and early-phase settings. The framework draws from international regulatory standards set by agencies such as the FDA, EMA, and ISO, and covers several areas, such as facility management, personnel, equipment management, supplier management, audits, among others.
-
1 week ago | 
themedicinemaker.com | Stephanie Vine
The Leukemia & Lymphoma Society (LLS) has been funding research since 1949 and has helped support several FDA-approved therapies, including Yescarta, Vyxeos, Elzonris, and Copiktra. In January 2025, Lore Gruenbaum became LLS’s Chief Scientific Officer. In part 1 of our interview with Gruenbaum, we learned about her career spanning big pharma and biotech. Here, we take a deep dive into the work of LLS, including success stories and the pressing research gaps that remain.
-
2 weeks ago | 
themedicinemaker.com | Stephanie Vine
Pfizer scientists discovered Viagra (sildenafil citrate) in the 1980s when they were looking for potential treatments for angina. Results for sildenafil in angina were not looking promising and the drug was at risk of being scrapped. At one of the final trials in Merthyr Tydfil, UK, participants had to stay at the clinic overnight. In the morning, a questionnaire was given out.
-
2 weeks ago | 
themedicinemaker.com | Stephanie Vine
GSK is collaborating with the UK’s Dementia Research Institute and Health Data Research UK to explore a potential link between GSK’s RZV shingles vaccine and a reduced risk of dementia. Data from several observational studies appears to suggest a link may exist, with the latest study being published at the start of April in Nature. In this study, research used health data from Wales, where eligibility for the shingles vaccine is based on a person's exact date of birth.
